[144] Madrigal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Madrigal Pharmaceuticals (MDGL) submitted a Form 144 reporting proposed and recent insider sales of common stock. The filer disclosed a proposed sale of 7,279 shares through Morgan Stanley Smith Barney with an aggregate market value of $3,303,210.20, listing Nasdaq as the exchange and an approximate sale date of 09/09/2025. The shares were acquired as a Restricted Stock Unit grant that vested on 09/08/2025 and the payment/nature of the transaction is recorded as vesting of RSUs. The filing also reports that William John Sibold sold 7,616 shares on 08/21/2025 for $3,047,756.28. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: An insider reported an RSU vesting and a proposed sale of 7,279 shares; a prior sale of 7,616 shares was also disclosed.

The filing documents routine insider activity: an RSU grant that vested on 09/08/2025 leading to a proposed sale of the vested shares via Morgan Stanley on 09/09/2025, with an aggregate market value of $3,303,210.20. It also records an earlier sale by William John Sibold on 08/21/2025 of 7,616 shares for $3,047,756.28. This form fulfils Rule 144 disclosure requirements and provides transparent timing and amounts for the transactions. The information is transactional and evidentiary rather than descriptive of company performance.

Corporate Governance Expert

TL;DR: The filing reflects compliance with disclosure rules for insider sales tied to RSU vesting; no additional governance issues are disclosed.

The document includes the representational language required by Form 144 and states the nature of acquisition (Restricted Stock Unit grant) and means of sale. It does not indicate adoption of a Rule 10b5-1 trading plan or disclose any undisclosed material adverse information. From a governance perspective, the filing is a standard disclosure of insider monetization following vesting events.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	7279	3303210.20	22289014	09/09/2025	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/08/2025	Restricted Stock Unit Grant	Issuer			7279	09/08/2025	Vesting of Restricted Stock Units

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
William John Sibold c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	08/21/2025	7616	3047756.28

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider sales are reported for Madrigal Pharmaceuticals (MDGL)?

The filing reports a proposed sale of 7,279 shares (aggregate market value $3,303,210.20) and a completed sale of 7,616 shares on 08/21/2025 for $3,047,756.28.

How were the shares being sold acquired?

The shares subject to the proposed sale were acquired via a Restricted Stock Unit grant that vested on 09/08/2025.

Which broker is handling the proposed sale?

The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the Nasdaq Stock Market.

When is the approximate date of the proposed sale?

The filing lists the approximate date of sale as 09/09/2025.

Who sold shares on 08/21/2025 and how many were sold?

William John Sibold sold 7,616 shares on 08/21/2025 for $3,047,756.28.